Triple Threat: Three Primary Malignancies Simultaneously Involving Three Genitourinary Organs.
Journal
Case reports in urology
ISSN: 2090-696X
Titre abrégé: Case Rep Urol
Pays: United States
ID NLM: 101580193
Informations de publication
Date de publication:
2023
2023
Historique:
received:
20
01
2023
revised:
20
03
2023
accepted:
27
03
2023
medline:
27
4
2023
pubmed:
27
4
2023
entrez:
27
4
2023
Statut:
epublish
Résumé
Statistically, the chance of having concurrent renal cell carcinoma (RCC), urothelial carcinoma of the bladder (UC), and a neuroendocrine tumor (NET) of the renal parenchyma is less than one in a trillion. Herein, we describe an unusual case of a 67-year-old female who presented with bilateral flank pain and severe gross hematuria. Cross-sectional imaging revealed two large heterogeneous, endophytic renal masses with a single enlarged paracaval lymph node. Diagnostic cystoscopy was performed for completion of gross hematuria evaluation and revealed a concurrent papillary bladder tumor. Percutaneous biopsies of bilateral renal masses revealed clear cell RCC involving the left kidney and well-differentiated NET involving the right kidney, and transurethral resection of the bladder tumor revealed high-grade nonmuscle invasive urothelial carcinoma. The patient elected to undergo bilateral nephroureterectomy, radical cystectomy, and retroperitoneal and pelvic lymphadenectomy. Final pathology confirmed the presence of three different malignancies: noninvasive high-grade papillary UC of the bladder (pTaN0), left renal clear cell RCC (pT2bN0), right renal well-differentiated NET, and a single paracaval lymph nodes positive for metastatic NET (pT2aN1).
Identifiants
pubmed: 37101564
doi: 10.1155/2023/3242986
pmc: PMC10125746
doi:
Types de publication
Case Reports
Langues
eng
Pagination
3242986Informations de copyright
Copyright © 2023 Katharina Mitchell et al.
Déclaration de conflit d'intérêts
The authors declare that they have no conflicts of interest.
Références
Neuroendocrinology. 2017;104(1):26-32
pubmed: 26731483
Neoplasia. 2017 Dec;19(12):991-1002
pubmed: 29091800
J Urol. 2009 Sep;182(3):844-53
pubmed: 19616235
Nat Commun. 2021 Jul 29;12(1):4612
pubmed: 34326338
Front Endocrinol (Lausanne). 2021 Feb 05;11:624251
pubmed: 33613455
J Clin Oncol. 2014 Jun 20;32(18):1968-76
pubmed: 24821879
BMC Urol. 2017 Jan 12;17(1):6
pubmed: 28081704
Medicine (Baltimore). 2019 Aug;98(31):e16684
pubmed: 31374051
Crit Rev Oncol Hematol. 2013 Sep;87(3):256-64
pubmed: 23478151
PLoS One. 2011 Apr 14;6(4):e18583
pubmed: 21533174
Cureus. 2021 Nov 19;13(11):e19743
pubmed: 34812336
World J Surg Oncol. 2018 Jan 25;16(1):16
pubmed: 29370814
Indian J Urol. 2009 Apr;25(2):155-60
pubmed: 19672338
Medicine (Baltimore). 2021 Feb 26;100(8):e24714
pubmed: 33663082
Cancer Cytopathol. 2017 Jun;125(6):407-415
pubmed: 28334518
J Urol. 2021 Aug;206(2):199-208
pubmed: 34115547